This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
Kerendia®▼(finerenone) is indicated for the treatment of chronic kidney disease (Stages 3 and 4 with albuminuria) associated with type 2 diabetes in adult patients.
For adult patients with CKD and T2D
Despite standard of care, patients with CKD in T2D are at risk of CV events, ESKD, and dialysis
CKD is ~2x more prevalent in patients with T2D vs those without
Life expectancies of patients with both T2D and CKD are on average 16 years shorter than those without
Patients with both T2D and CKD are ~3x more likely to die of CV-related causes than patients with T2D alone
CKD=chronic kidney disease; CV=cardiovascular; ESKD=end-stage kidney disease; T2D=type 2 diabetes
PP-KER-GB-0469 | March 2024
- Referencesexpand_more
- 1Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1-S115
- 2Koye DN, et al. Adv Chronic Kidney Dis. 2018:25(2):121-132.
- 3Wen CP, et al. Kidney Int. 2017;92(2):388–396
- 4Afkarian M, et al. J Am Soc Nephr. 2013;24(2):302–308.